MS-325 injectable magnetic resonance imaging contrast agent: Phase II

By WIR Staff | Jul 20, 1998 | 7:00 AM GMT

EPIX and partner Mallinckrodt Inc. (St. Louis, Mo.) reported results of a

Read the full 126 word article

How to gain access

Continue reading with a
two-week free trial.